Palvella Therapeutics (PVLA) Institutional Ownership $76.22 +6.32 (+9.04%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Palvella Therapeutics (NASDAQ:PVLA)CurrentInstitutional OwnershipPercentage40.11%Number ofInstitutional Buyers(last 12 months)31TotalInstitutional Inflows(last 12 months)$74.01MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$3.71M Get PVLA Insider Trade Alerts Want to know when executives and insiders are buying or selling Palvella Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data PVLA Institutional Buying and Selling by Quarter Palvella Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025Frazier Life Sciences Management L.P.722,400$16.28M0.7%+4.7%6.532% 8/15/2025BNP Paribas Financial Markets4,630$104K0.0%N/A0.042% 8/15/2025Bank of America Corp DE4,174$94K0.0%-45.1%0.038% 8/14/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.3,750$85K0.0%N/A0.034% 8/14/2025OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 43,994$992K0.1%-9.6%0.398% 8/13/2025Marshall Wace LLP49,077$1.11M0.0%+61.7%0.444% 8/13/2025New York State Common Retirement Fund4,900$110K0.0%N/A0.044% 8/13/2025Adams Street Partners LLC298,986$6.74M4.7%-27.0%2.703% 8/12/2025XTX Topco Ltd17,701$399K0.0%N/A0.160% 8/12/2025Rhumbline Advisers9,956$224K0.0%N/A0.090% Get the Latest News and Ratings for PVLA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2025JPMorgan Chase & Co.3,245$73K0.0%+108,066.7%0.029% 8/8/2025Police & Firemen s Retirement System of New Jersey1,639$37K0.0%N/A0.015% 8/8/2025Geode Capital Management LLC173,986$3.92M0.0%+84.7%1.574% 7/22/2025Strid Group LLC18,166$409K0.1%-37.8%0.164% 7/14/2025Clio Asset Management LLC91,508$2.06M1.6%N/A0.828% 6/27/2025Goldman Sachs Group Inc.19,053$533K0.0%N/A0.172% 5/16/2025Woodline Partners LP194,167$5.44M0.0%N/A1.758% 5/16/2025Goldman Sachs Group Inc.19,053$533K0.0%N/A0.173% 5/16/2025Millennium Management LLC269,837$7.55M0.0%N/A2.444% 5/16/2025AWM Investment Company Inc.69,416$1.94M0.3%N/A0.629% 5/15/2025Frazier Life Sciences Management L.P.690,012$19.31M0.9%+5.5%6.248% 5/15/2025DAFNA Capital Management LLC43,348$1.21M0.3%-39.3%0.393% 5/6/2025Royce & Associates LP71,514$2.00M0.0%N/A0.648% 4/25/2025Strid Group LLC29,219$818K0.1%N/A0.265% 4/23/2025Spire Wealth Management2,516$70K0.0%N/A0.023% 2/19/2025Toronto Dominion Bank13,211$159K0.0%N/A0.118% 2/18/2025Frazier Life Sciences Management L.P.653,892$7.85M0.3%N/A5.828% 2/17/2025Toronto Dominion Bank13,211$159K0.0%N/A0.118% 2/17/2025Suvretta Capital Management LLC714,463$8.57M0.3%N/A6.367% 2/17/2025DAFNA Capital Management LLC71,452$857K0.2%N/A0.637% 2/17/2025Cresset Asset Management LLC20,911$251K0.0%N/A0.186% 2/17/2025Citadel Advisors LLC10,408$125K0.0%N/A0.093% 2/17/2025BVF Inc. IL696,555$8.36M0.3%N/A6.208% 2/17/2025Adams Street Partners LLC409,666$4.92M4.4%N/A3.651% 2/14/2025Samsara BioCapital LLC679,486$8.15M1.1%N/A6.056% 2/14/2025Nantahala Capital Management LLC250,062$3.00M0.1%N/A2.229% 2/14/2025Blue Owl Capital Holdings LP250,062$3.00M0.7%N/A2.229% 2/13/2025Renaissance Technologies LLC21,371$256K0.0%N/A0.190% 2/13/2025ADAR1 Capital Management LLC144,641$1.74M0.3%N/A1.289% 2/12/2025Geode Capital Management LLC14,270$171K0.0%N/A0.127% 2/7/2025BML Capital Management LLC42,130$506K0.3%N/A0.375% (Data available from 1/1/2016 forward) PVLA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of PVLA shares? During the previous two years, 33 institutional investors and hedge funds held shares of Palvella Therapeutics. The most heavily invested institutionals were Frazier Life Sciences Management L.P. ($16.28M), Suvretta Capital Management LLC ($8.57M), BVF Inc. IL ($8.36M), Samsara BioCapital LLC ($8.15M), Millennium Management LLC ($7.55M), Adams Street Partners LLC ($6.74M), and Woodline Partners LP ($5.44M).Learn more on Palvella Therapeutics' institutional investors. What percentage of Palvella Therapeutics' stock is owned by institutional investors? 40.11% of Palvella Therapeutics' stock is owned by institutional investors. Learn more on PVLA's institutional investor holdings. Which institutional investors have been buying Palvella Therapeutics' stock? Of the 31 institutional investors that purchased Palvella Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Frazier Life Sciences Management L.P. ($722.40K), Suvretta Capital Management LLC ($714.46K), BVF Inc. IL ($696.56K), Samsara BioCapital LLC ($679.49K), Adams Street Partners LLC ($409.67K), Millennium Management LLC ($269.84K), and Blue Owl Capital Holdings LP ($250.06K). How much institutional buying is happening at Palvella Therapeutics? Institutional investors have bought a total of 4,984,919 shares in the last 24 months. This purchase volume represents approximately $74.01M in transactions. Which of Palvella Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Palvella Therapeutics stock in the last 24 months: Adams Street Partners LLC ($110.68K), DAFNA Capital Management LLC ($28.10K), Strid Group LLC ($11.05K), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC ($4.67K), and Bank of America Corp DE ($3.44K). How much institutional selling is happening at Palvella Therapeutics? Institutional investors have sold a total of 157,942 shares in the last 24 months. This volume of shares sold represents approximately $3.71M in transactions. Related Companies CNTA Institutional Ownership XENE Institutional Ownership CGON Institutional Ownership TARS Institutional Ownership RARE Institutional Ownership MOR Institutional Ownership KNSA Institutional Ownership IMVT Institutional Ownership HCM Institutional Ownership OGN Institutional Ownership This page (NASDAQ:PVLA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
